Fibrovas Tablet is a combination medication containing Atorvastatin 10mg and Fenofibrate 160mg, designed to manage lipid disorders effectively. Atorvastatin, a statin, works by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis, thereby reducing low-density lipoprotein (LDL) cholesterol and total cholesterol levels. Fenofibrate, a fibric acid derivative, primarily lowers triglycerides and can modestly increase high-density lipoprotein (HDL) cholesterol by activating peroxisome proliferator-activated receptors (PPARs). Together, these agents provide a comprehensive approach to dyslipidemia, especially in patients with mixed hyperlipidemia or those at high risk of cardiovascular disease. Fibrovas is indicated for patients who have not achieved adequate lipid control with monotherapy or lifestyle modifications alone. It helps reduce the risk of atherosclerosis, coronary artery disease, and related complications by improving lipid profiles. The tablet should be taken as prescribed by a healthcare professional, typically once daily with food to enhance absorption and minimize gastrointestinal discomfort. Regular monitoring of liver function tests, lipid levels, and renal function is recommended during therapy. Patients should inform their doctor of any history of liver or kidney disease, muscle pain, or unexplained weakness while using Fibrovas.